AstraZeneca to pay $5.52 million to resolve SEC foreign bribery case

NEW YORK (Reuters) - U.S. regulators said on Tuesday that AstraZeneca Plc will pay $5.52 million to resolve a foreign bribery probe into improper payments by its sales and marketing staff to officials at state-controlled health care providers in China and Russia.

AstraZeneca to pay $5.52 million to resolve SEC foreign bribery case
Read More


Bagikan Berita Ini